Phase 2 study of dasatinib in Chinese patients with chronic myeloid leukemia (CML) in chronic phase (CP) or advanced phase who are resistant to or intolerant of imatinib (IM)

被引：0
|
作者：
Wang, Jianxiang [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ,12 ,13 ]
Huang, Xiaojun
Hu, Jianda
Li, Jianyong
Jin, Jie
Meng, Fanyi
Shen, Zhixiang
Liu, Ting
Wu, Depei
Wang, Jianmin
机构：
[1] Chinese Acad Med Sci, Inst Hematol, Beijing, Peoples R China
[2] Chinese Acad Med Sci, Blood Dis Hosp, Beijing, Peoples R China
[3] Peking Univ, Inst Hematol, Beijing, Peoples R China
[4] Peking Univ, Peoples Hosp, Beijing, Peoples R China
[5] Fujian Med Univ, Union Hosp, Fuzhou, Peoples R China
[6] Fujian Med Univ, Union Hosp, Fuzhou, Peoples R China
[7] Jiangsu Prov Hosp, Suzhou, Peoples R China
[8] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Hangzhou, Zhejiang, Peoples R China
[9] Southern Med Univ, Nanfang Hosp, Guangzhou, Guangdong, Peoples R China
[10] Shanghai Jiao Tong Univ, Shanghai Ruijin Hosp, Shanghai, Peoples R China
[11] Sichuan Univ, West China Hosp, Chengdu, Peoples R China
[12] Soochow Univ, Affiliated Hosp 1, Suzhou, Peoples R China
[13] Second Mil Med Univ, Changhai Hosp, Shanghai, Peoples R China
来源：
LEUKEMIA & LYMPHOMA | 2013年 / 54卷
关键词：
CML; dasatinib; imatinib-resistance;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3
引用
收藏
页码：3 / +
页数：3
相关论文
共 50 条
  • [41] Long-term safety and efficacy of dasatinib in the treatment of chronic-phase chronic myeloid leukemia patients resistant or intolerant to imatinib
    Shoumariyeh, Khalid
    von Bubnoff, Nikolas
    BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY, 2014, 4 : 81 - 89
  • [42] Second-Line Bosutinib in Patients with Chronic Phase Chronic Myeloid Leukemia (CP CML) Resistant or Intolerant to Prior Imatinib: An 8-Year Update
    Brummendorf, Tim H.
    Gambacorti-Passerini, Carlo
    Kim, Dong-Wook
    Goh, Yeow Tee
    Dyagil, Iryna
    Pagnano, Katia B.
    Batai, Arpad
    Turkina, Anna G.
    Aguiar, Jean M.
    Leip, Eric
    Cortes, Jorge E.
    BLOOD, 2017, 130
  • [43] Bosutinib As Second-Line Therapy in Patients (Pts) with Chronic Phase Chronic Myeloid Leukemia (CP CML) Resistant or Intolerant to Prior Imatinib: 60-Month Update of a Phase 1/2 Study
    Bruemmendorf, Tim H.
    Cortes, Jorge E.
    Khoury, H. Jean
    Kantarjian, Hagop M.
    Kim, Dong-Wook
    Schafhausen, Philippe
    Zeremski, Mirjana
    Shapiro, Mark
    Leip, Eric
    Gambacorti-Passerini, Carlo
    Lipton, Jeffrey H.
    BLOOD, 2014, 124 (21)
  • [44] Imatinib dose escalation is effective in patients with chronic myeloid leukemia in chronic phase (CML-CP)
    Kantarjian, Hagop M.
    Druker, Brian J.
    Guilhot, Francois
    Cortes, Jorge
    O'Brien, Stephen G.
    Krahnke, Tillmann
    Larson, Richard A.
    BLOOD, 2007, 110 (11) : 317A - 317A
  • [45] A phase II study of nilotinib administered to imatinib resistant or intolerant patients with chronic myelogenous leukemia (CML) in accelerated phase (AP)
    le Coutre, P.
    Gattermann, N.
    Hochhaus, A.
    Larson, R.
    Weitzman, A.
    Haque, A.
    Giles, F.
    O'Brien, S. G.
    Kantarjian, H. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [46] BOSUTINIB FOR THIRD-LINE TREATMENT OF CHRONIC PHASE (CP) CHRONIC MYELOID LEUKEMIA (CML) FOLLOWING RESISTANCE OR INTOLERANCE TO IMATINIB (IM) AND DASATINIB (D)
    Gambacorti-Passerini, C.
    Cortes, J.
    Zaritskey, A.
    Bullorsky, E.
    Navarro, J.
    Khoury, H.
    Besson, N.
    McMullan, T.
    Arkin, S.
    Bruemmendorf, T.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 57 - 58
  • [47] Dasatinib (D) in patients with accelerated phase chronic myeloid leukemia (AP-CML) who are resistant or intolerant to imatinib: Results of the CA180005 'START-A' study.
    Talpaz, M.
    Apperley, J. F.
    Kim, D. W.
    Silver, R. T.
    Bullorsky, E. O.
    Cheng, S.
    Iyer, M.
    Guilhot, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 343S - 343S
  • [48] Phase 2 Study of Dasatinib with and without Venetoclax in Patients with Early Chronic Phase Chronic Myeloid Leukemia (ECP-CML)
    Haddad, Fadi G.
    Jabbour, Elias
    Sasaki, Koji
    Nasr, Lewis
    Huang, Xuelin
    Issa, Ghayas C.
    Ravandi, Farhad
    Garcia-Manero, Guillermo
    Kadia, Tapan M.
    Daver, Naval
    Valero, Yesid Alvarado
    Nasnas, Cedric
    Ohanian, Maro
    Short, Nicholas J.
    Masarova, Lucia
    Zoghbi, Marianne
    Nasnas, Patrice Eric
    Montalban-Bravo, Guillermo
    Skinner, Jeffrey
    Pierce, Sherry
    Andreeff, Michael
    Kantarjian, Hagop M.
    BLOOD, 2023, 142
  • [49] Phase II study of dasatinib in children and adolescents with newly diagnosed chronic phase chronic myelogenous leukemia (CP-CML) or Philadelphia-positive (Ph plus ) leukemias resistant or intolerant to imatinib
    Rosenberg, J. A.
    Derreumaux, D.
    Gore, L.
    Kearns, P.
    Baruchel, A.
    Barrett, T.
    Zwaan, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [50] SAFETY AND EFFICACY OF SECOND-LINE BOSUTINIB (SKI-606) IN IMATINIB RESISTANT OR INTOLERANT CHRONIC PHASE (CP) CHRONIC MYELOID LEUKEMIA (CML)
    Brummendorf, T.
    Cortes, J.
    Turkina, A.
    Masszi, T.
    Assouline, S.
    Durrant, S.
    Volkert, A.
    Wang, J.
    Arkin, S.
    Gambacorti-Passerini, C.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 468 - 468
12345